Navigation Links
Blue Cross of California Introduces Pay-for-Performance Hospital Program
Date:3/19/2008

California hospitals implement Blue Cross of California's Quality-in-Sights

Hospital Incentive Program

THOUSAND OAKS, Calif., March 19 /PRNewswire/ -. Blue Cross of California (Blue Cross) today announced the introduction of its Quality-in-Sights Hospital Incentive Program (Q-HIP) in 23 California hospitals.

Q-HIP is designed to align financial incentives with quality improvements. It uses select indicators that have been identified for public reporting by the California Hospital Assessment and Reporting Taskforce (CHART) to assess hospital performance. These indicators are also promulgated by several national standard setting organizations, including The Joint Commission, the Leapfrog Group and the National Quality Forum (NQF).

To be eligible for Q-HIP, hospitals must submit their data to CHART, which was established in 2004 to develop a statewide hospital performance reporting system. Hospitals can earn Q-HIP adjustments to inpatient hospital fixed payment rates depending on their Q-HIP score, which is based on patient safety, clinical processes and outcomes, and patient experience. There is no downside adjustment based on Q-HIP performance.

Blue Cross's goal is to improve performance across the provider network and minimize the variation in quality. "We are committed to helping our members by supporting change that improves the quality and safety of health care," said Leslie Margolin, president and general manager of Blue Cross. "Consumers have demonstrated an increased demand for value purchasing, and we have responded to that need."

"Blue Cross has already established physician measurement and reward programs," said Margolin. "Now we are ready to introduce a process to measure the quality of hospitals within our network."

Hospitals that currently participate in Q-HIP include: Pacifica Hospital of the Valley, USC University Hospital, Desert Regional Medical Center, Fountain Valley Regional H
'/>"/>

SOURCE Blue Cross of California
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Red Cross Announces an Extension for Emotional Support Assistance for 2005 Hurricane Survivors
2. Capital BlueCross Receives Prestigious Brand Excellence Award From The Blue Cross & Blue Shield Association
3. Wellness Initiative for 2008 Tour de Georgia Presented by AT&T Led by New Partnership With Blue Cross and Blue Shield of Georgia
4. Physicians and Patients Across Texas Decry Trend of Unauthorized Generic Drug Substitutions
5. Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs
6. Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators
7. Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia
8. Blue Cross and Blue Shields Blue Distinction(R) Designation Improves Healthcare by Focusing on Quality
9. Professional Quarterback Matt Leinart Teams Up With American Red Cross to Promote CPR/AED Awareness
10. Life Spine Adds New Lynx(TM) Cross Connector to Its Lumbar Fixation Offering
11. Disability by Denial - Blue Cross Rejects Critical Surgery for Orange County ICU Nurse - Woman Possibly Left Disabled by Denial
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast 13452 1Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast 13452 2More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 1More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 2More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 3More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 4More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 5Sanofi Pasteur Submits Supplemental Application for A 28H1N1 29 Pandemic Vaccine to U S FDA 4835 1Sanofi Pasteur Submits Supplemental Application for A 28H1N1 29 Pandemic Vaccine to U S FDA 4835 2Sanofi Pasteur Submits Supplemental Application for A 28H1N1 29 Pandemic Vaccine to U S FDA 4835 3